- Home
- MNOV vs SRTS Comparison
MNOV vs SRTS Comparison
Compare MNOV & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | SRTS |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 65.5M |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MNOV | SRTS |
|---|---|---|
| Price | $1.40 | $4.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $7.50 | $6.67 |
| AVG Volume (30 Days) | ★ 55.9K | 44.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $27,482,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.13 | $3.03 |
| 52 Week High | $1.96 | $5.92 |
Technical Indicators
Market Signals| Indicator | MNOV | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 53.61 |
| Support Level | $1.21 | $4.15 |
| Resistance Level | $1.43 | $4.80 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 24.25 | 60.76 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.